A systematic study on the treatment of hepatitis B-related hepatocellular carcinoma with drugs based on bioinformatics and key target reverse network pharmacology and experimental verification

被引：0
|
作者：
Shenghao Li
Liyuan Hao
Xiaoyu Hu
Luya Li
机构：
[1] Chengdu University of Traditional Chinese Medicine,Department of Pharmacy Department
[2] Hospital of Chengdu University of Traditional Chinese Medicine,undefined
[3] The Fourth Hospital of Hebei Medical University,undefined
来源：
Infectious Agents and Cancer | / 18卷
关键词：
Hepatitis B virus-associated hepatocellular carcinoma; CDK1; CCNB1; Traditional Chinese medicine; Quercetin; Celastrol; Cantharidin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Bioinformatics combined with network pharmacology and experimental validation to identify key biomarkers of hepatocellular carcinoma and corresponding compounds in Radix Astragali and Pueraria Mirifica
    Li, Mohan
    Liu, Bang
    Xian, Minghua
    Wang, Shumei
    Liu, Peiyi
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, : 5351 - 5371
  • [32] Bioinformatics and network pharmacology-based study to elucidate the multi-target pharmacological mechanism of the indigenous plants of Medina valley in treating HCV-related hepatocellular carcinoma
    Alamri, Mubarak A.
    SAUDI PHARMACEUTICAL JOURNAL, 2023, 31 (06) : 1125 - 1138
  • [33] Prognostic factors and recurrence of hepatitis B-related hepatocellular carcinoma after argon-helium cryoablation: a prospective study
    Wang, Chunping
    Lu, Yinying
    Chen, Yan
    Feng, Yongyi
    An, Linjing
    Wang, Xinzhen
    Su, Shuhui
    Bai, Wenlin
    Zhou, Lin
    Yang, Yongping
    Xu, Dongping
    CLINICAL & EXPERIMENTAL METASTASIS, 2009, 26 (07) : 839 - 848
  • [34] Machine learning algorithms based on proteomic data mining accurately predicting the recurrence of hepatitis B-related hepatocellular carcinoma
    Feng, Gong
    He, Na
    Xia, Harry Hua-Xiang
    Mi, Man
    Wang, Ke
    Byrne, Christopher D.
    Targher, Giovanni
    Yuan, Hai-Yang
    Zhang, Xin-Lei
    Zheng, Ming-Hua
    Ye, Feng
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 (11) : 2145 - 2153
  • [35] Prognostic factors and recurrence of hepatitis B-related hepatocellular carcinoma after argon-helium cryoablation: a prospective study
    Chunping Wang
    Yinying Lu
    Yan Chen
    Yongyi Feng
    Linjing An
    Xinzhen Wang
    Shuhui Su
    Wenlin Bai
    Lin Zhou
    Yongping Yang
    Dongping Xu
    Clinical & Experimental Metastasis, 2009, 26 : 839 - 848
  • [36] Not all of the patients with hepatitis B-related hepatocellular carcinoma require endoscopic screening for esophageal varices: a large cohort study
    Chang, C. -Y.
    Su, C. -W.
    Chen, P. -H.
    Hou, M. -C.
    Lee, P. -C.
    Lin, H. -C.
    Huang, Y. -H.
    Huo, T. -I.
    Wu, J. -C.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S139 - S140
  • [37] Network Pharmacology-Based Study on the Mechanism of Scutellariae Radix for Hepatocellular Carcinoma Treatment
    Wang, Qian
    Liang, Yan
    Peng, Can
    Jiang, Peng
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2020, 2020
  • [38] Utilization of Antiviral Therapy for Patients With Hepatitis B-Related Hepatocellular Carcinoma: A Nationwide Real-World US Study
    Kudaravalli, Sahith
    Kam, Leslie Y.
    Huang, Daniel Q.
    Cheung, Ramsey
    Nguyen, Mindie H.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (13) : 3305 - 3313.e4
  • [39] Mechanism of Dahuang–Dangshen drug pairs in the treatment of HCC based on network pharmacology, bioinformatics, molecular docking and experimental verification
    Pan Yu
    Shuhui Feng
    Weifan Wang
    Weiya Cao
    Yongchang Cao
    Medical Oncology, 42 (5)
  • [40] Investigation and experimental validation of curcumin-related mechanisms against hepatocellular carcinoma based on network pharmacology
    Chen, Yang
    Li, Qian
    Ren, Sisi
    Chen, Ting
    Zhai, Bingtao
    Cheng, Jiangxue
    Shi, Xiaoyan
    Song, Liang
    Fan, Yu
    Guo, Dongyan
    JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B, 2022, 23 (08): : 682 - 698
12345